Truemeds eyes a $90 million acquisition of DealShare at a valuation 95% below its 2021 peak.
Truemeds, India’s pharmaceutical e-commerce and telemedicine platform, is in advanced discussions to acquire DealShare, a group-buying marketplace for healthcare products, at an enterprise valuation of approximately $90 million, according to multiple industry sources.1 The acquisition price represents a dramatic 95 percent decline from DealShare’s peak valuation of ₹1,800+ crore during the 2021 fintech and e-commerce boom, exemplifying the valuation correction and consolidation sweeping India’s healthcare and consumer tech sectors.1
DealShare, founded to enable group purchases of healthcare products at discounted prices, raised over $60 million from marquee investors including Sequoia Capital and DST Global at peak valuations exceeding ₹1,500 crore.1 The platform struggled to achieve sustainable unit economics as user acquisition costs exceeded lifetime customer value, leading to operational challenges and significant workforce reductions.1
Truemeds’ acquisition of DealShare would consolidate two struggling healthcare e-commerce players, combining DealShare’s user base and distribution channels with Truemeds’ pharmacy network, telemedicine capabilities, and enterprise B2B partnerships.1 The consolidated platform aims to achieve profitability through improved unit economics, reduced customer acquisition redundancy, and cross-selling opportunities across pharmacy, telemedicine, and diagnostic services.
The acquisition reflects broader consolidation patterns in Indian e-commerce: as venture capital availability tightens, unprofitable startups resort to M&A rather than independent survival.1 Previous consolidations include Swiggy acquiring Daily, Meesho acquiring Agritech startups, and various healthtech mergers addressing market saturation and investor pressure for profitability.1
DealShare investors, including Sequoia Capital and DST Global, face significant mark-to-market losses on their investments, reflecting the stark gap between 2021 peak valuations and current acquisition multiples. The acquisition validates investor thesis that healthcare e-commerce requires scale, capital efficiency, and diversified revenue streams beyond pure marketplace models.1
